LeipoldRRaalFIshakJet al.The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. European Journal of Preventive Cardiology2017; 24: 1843–1850.
2.
CuchelMBruckertEGinsbergHNet al.European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J2014; 35: 2146–2157.
3.
WongBVillaGKutikovaLet al.The magnitude of increased cardiovascular (CV) risk associated with familial hypercholesterolemia (FH) for use in economic analyses. Value Health2015; 18: A340–A340.
4.
BruckertESahebSBontéJRet al.Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey. Atheroscler Suppl2014; 15: 46–51.
5.
BruckertEKalmykovaOBittarRet al.Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis2017; 257: 130–137.
6.
ThompsonGRSeedMNaoumovaRPet al.Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. Atherosclerosis2015; 243: 328–333.
7.
FerenceBAGinsbergHNGrahamIet al.Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J2017; 38(32): 2459–2472.
8.
BlomDJAvernaMRMeagherEAet al.Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation2017; 136: 332–335.
9.
LiuXMenPWangYet al.Efficacy and safety of lomitapide in hypercholesterolemia. Am J Cardiovasc Drugs2017; 17: 299–309.
